1310796-19-0

Basic information

• Product Name: (Z)-3-((dimethylamino)methylene)-4-oxopiperidine-1-carboxylic acid tert-butyl ester
• Synonyms: (Z)-3-((dimethylamino)methylene)-4-oxopiperidine-1-carboxylic acid tert-butyl ester
• CAS NO: 1310796-19-0
• Molecular Weight: 254.329
• Mol File: 1310796-19-0.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: (Z)-3-((dimethylamino)methylene)-4-oxopiperidine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (Z)-3-((dimethylamino)methylene)-4-oxopiperidine-1-carboxylic acid tert-butyl ester(1310796-19-0)
• EPA Substance Registry System: (Z)-3-((dimethylamino)methylene)-4-oxopiperidine-1-carboxylic acid tert-butyl ester(1310796-19-0)

Safety Data

• Hazardous Substances Data: 1310796-19-0(Hazardous Substances Data)

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 68-12-2 N,N-dimethyl-formamide 
• 127-19-5 N,N-dimethyl acetamide 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 

Downstream Products

• 192869-49-1 tert-butyl-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-carboxylate 
• 869198-95-8 2-amino-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-carboxylic acid tert-butyl ester 
• 100501-57-3 tert-butyl 2-methyl-6,7-dihydro-2H-pyrazolo(4,3-c)pyridine-5(4H)-carboxylate 
• 230301-11-8 1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridine-5-carboxylic acid tert-butyl ester 
• 1313997-98-6 6-{(3S,5R)-3,5-dimethyl-4-[2-oxo-2-(2-phenyl-2,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)ethyl]piperazin-1-yl}nicotinic acid ethyl ester 

Relevant articles and documents

FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES

The present invention discloses compounds according to Formula I: Wherein A, B, R1, R2, and Cy are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, pain, and/or abnormal angiogenesis associated diseases by administering the compounds of the invention.

C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS

The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.

Azacyclic derivative as well as preparation method and medical use thereof

The invention relates to an azacyclic derivative as well as a preparation method and medical use thereof and particularly relates to an azacyclic derivative represented by a general formula (I) (shownin the description), a preparation method thereof, a pharmaceutical composition containing the derivative and use of the derivative as an SMO antagonist, particularly in the treatment of diseases such as cancer related to Hedgehog signal channels. The definitions of groups in the general formula (I) are same as the definitions in the description.